NCT01627587已完成1 期
A Two Cohort, Open-label Study to Evaluate the Pharmacokinetics of GSK2847065, the Metabolite of Retosiban (GSK221149) After Single and Repeat Oral Doses, the Pharmacokinetics of GSK221149 Coadministered With a High Fat Meal, and the Pharmacokinetics of GSK221149 Coadministered With an Inhibitor of CYP3A4 (Ketoconazole)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 46
- 试验地点
- 1
- 主要终点
- Area under the curve, half life
研究概览
简要总结
This is a two part study. Part A of the study will evaluate the metabolites of GSK221149 following single and repeat oral dosing and will also assess the pharmacokinetics of GSK221149 when administered with a potent CYP3A4 inhibitor Ketoconazole. Part B of the study will look at the pharmacokinetics of GSK221149 following a high fat meal.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •ALT, alkaline phosphatase and bilirubin less than and equal to 1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin less than 35%).
- •Single [QTc, QTcB or QTcF] less than 450 msec; or QTc less than 480 msec in subjects with Bundle Branch Block.
- •Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator and the GSK Medical Monitor agree that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
- •Female subjects between 18 and 45 years of age inclusive, at the time of signing the informed consent.
- •A female subject is eligible to participate if she is of: Child-bearing potential and is abstinent or agrees to use one of the contraception methods listed in the protocol for an appropriate period of time (as determined by the product label or investigator) prior to the start of dosing to sufficiently minimize the risk of pregnancy at that point. Female subjects must agree to use contraception until 48 hours post last dose.
- •Body weight greater than 50 kg and BMI within the range 19-29.9 kg/m2 (inclusive).
排除标准
- •A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening
- •Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
- •A positive pre-study drug/alcohol/urine cotinine screen.
- •A positive test for HIV antibody.
- •History of regular alcohol consumption within 6 months of the study defined as: an average weekly intake of greater than 7 drinks for females. One drink is equivalent to 12 g of alcohol: 12 ounces (360 ml) of beer, 5 ounces (150 ml) of wine or 1.5 ounces (45 ml) of 80 proof distilled spirits.
- •The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
- •Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
- •Unable to refrain from the use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.
- •History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
- •Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
- •Pregnant females as determined by positive serum hCG test at screening or prior to dosing.
- •Lactating females.
- •Unwillingness or inability to follow the procedures outlined in the protocol.
- •Subject is mentally or legally incapacitated.
- •Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening.
- •Unable to refrain from consumption of red wine, seville oranges, grapefruit or grapefruit juice and/or pummels, exotic citrus fruits, grapefruit hybrids from 7 days prior to the first dose of study medication.
研究组 & 干预措施
Ketoconazole-Part A
Experimental
Healthy Female volunteers of child bearing potential will receive Treatment A, B and C
干预措施: GSK221149 750 mg (Drug)
Ketoconazole-Part A
Experimental
Healthy Female volunteers of child bearing potential will receive Treatment A, B and C
干预措施: Ketoconazole (Drug)
Ketoconazole-Part A
Experimental
Healthy Female volunteers of child bearing potential will receive Treatment A, B and C
干预措施: GSK221149 100 mg (Drug)
Food-Part B
Experimental
Healthy Female Volunteers of child bearing potential will receive Treament D and E
干预措施: GSK221149 750 mg Fasted (Drug)
Food-Part B
Experimental
Healthy Female Volunteers of child bearing potential will receive Treament D and E
干预措施: GSK221149 750 mg + Food (Drug)
结局指标
主要结局
Area under the curve, half life
时间窗: From Day 1- Day 11 of the study
Area under the curve, half life, when treate with ketconizole
时间窗: Day 1-11
次要结局
- 12 lead ECGs, safety labs, vital signs, heart rate, blood pressure(Day 1- Day 11 of the study)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
2 期
A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple SclerosisMultiple SclerosisNCT04075266Hoffmann-La Roche23
已完成
2 期
A Study to Evaluate SAGE-217 in Participants With Bipolar I/II Disorder With a Current Major Depressive EpisodeBipolar Disorder IBipolar Disorder IIMajor Depressive EpisodeNCT03692910Biogen35
已完成
1 期
Drug-Drug Interaction Study of Evobrutinib and Transporter SubstratesHealthyNCT05064488Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany40
进行中（未招募）
1 期
Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell MalignanciesPhase I: Relapsed or Refractory B-cell MalignanciesPhase II Cohort A: Relapsed or Refractory Mantle Cell LymphomaPhase II Cohort B: Relapsed or Refractory Chronic Lymphocytic LeukemiaNCT03932331AstraZeneca105
终止
1 期
Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients With Advanced Solid TumorsSolid Tumor, AdultNCT05307874ImCheck Therapeutics, an Ipsen company56